

On page 26 at line 8:

C5

D. Synthesis of the pentadecapeptide (Ref No. 9405): (SEQ ID NO: 8)

On Page 26 at line 10:

C6

$\text{CH}_3\text{CO}-\text{Leu}^1-\text{Arg}-\text{Ile}-\text{Val}-\text{Gln}-\text{Cys}-\text{Arg}-\text{Ser}-\text{Val}-\text{Glu}-\text{Gly}-\text{Ser}-\text{Cys}-\text{Gly}-\text{Phe}^{15}$ (cyclic disulfide) (SEQ ID NO: 8)

On Page 26 at line 21:

C7

E. Synthesis of the dicyclo-pentadecapeptide (Ref No. 9408): (SEQ ID NO: 11)

On page 30 at line 6:

C8

$\text{Tyr}-\text{Leu}-\text{Arg}-\text{Ile}-\text{Val}-\text{Gln}-\text{Cys}-\text{Arg}-\text{Ser}-\text{Val}-\text{Glu}-\text{Gly}-\text{Ser}-\text{Cys}-\text{Gly}-\text{Phe}$ (cyclic disulfide) (SEQ ID NO: 19)

In the Claims

Please amend the claims as follows:

but D2

1. (Amended) A peptide which comprises an analogue of the carboxyl-terminal sequence of a growth hormone, said carboxyl-terminal sequence containing amino acid residues 177-191 of human growth hormone:

$\text{Leu}-\text{Arg}-\text{Ile}-\text{Val}-\text{Gln}-\text{Cys}-\text{Arg}-\text{Ser}-\text{Val}-\text{Glu}-\text{Gly}-\text{Ser}-\text{Cys}-\text{Gly}-\text{Phe}$ (SEQ ID NO: 1),

or a corresponding sequence of a non-human mammalian growth hormone;
wherein in said analogue

C9

(i) amino acids at positions 182 and 189 of hGH are joined by a bond to promote a cyclic conformation; and/or

(ii) amino acids at positions 183 and 186 of hGH are joined by a salt bridge or a covalent bond;

C9
over or an organic or inorganic acid addition salt thereof.

Sub E1
13. (Amended) A peptide of the sequence:

X^1m -Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe- X^2n (SEQ ID NO: 2)

wherein X^1 and X^2 are each selected from the group consisting of L- or D- Arg, His, Lys and Tyr, and m and n are each 0, 1, 2 or 3 with the proviso that at least m or n is 1;

a cyclic disulfide thereof or an organic or inorganic acid addition salt thereof.

14. (Amended) A peptide of the sequence:

Y^1 -Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (SEQ ID NO: 3)

wherein Y^1 is selected from the group consisting of the desamino form (H), acetyl (CH_3CO-) and other acyl groups;

C10
a cyclic disulfide thereof or an organic or inorganic acid addition salt thereof.

Sub D3
15. (Amended) A peptide of the sequence:

Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe- Y^2 (SEQ ID NO: 4),

wherein Y^2 is selected from the group of $CONH_2$ and alkyl amide groups;

a scyclic disulfide thereof or an organic or inorganic acid addition salt thereof.

Sub E1
16. (Amended) A peptide which is selected from the group consisting of

Leu Arg Ile Val Gln Pen Arg Ser Val Glu Gly Ser Pen Gly Phe (SEQ ID NO: 15),

CH_3CO- Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 8),

H - Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 12),

Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe - $CONH_2$ (SEQ ID NO: 7),

Leu Arg Ile Val Gln Cys Lys Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 10),

Leu Arg Ile Val Gln Cys Lys Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 11),

|_____| (amide bond)

Tyr Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 19),

Lys Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 20),

Lys Lys Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 33),

Ala Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 22),

Leu Lys Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 21),

Leu Arg Ala Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 23),

Leu Arg Lys Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 6),

Leu Arg Ile Ala Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 24),

Leu Arg Ile Val Ala Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 25),

Leu Arg Ile Val Gln Cys Arg Ala Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 27),

Leu Arg Ile Val Gln Cys Arg Ser Ala Glu Gly Ser Cys Gly Phe (SEQ ID NO: 28),

Leu Arg Ile Val Gln Cys Arg Ser Val Glu Ala Ser Cys Gly Phe (SEQ ID NO: 30),

Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ala Cys Gly Phe (SEQ ID NO: 31),

Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Ala Phe (SEQ ID NO: 17),

Leu Arg Ile Val Gln Cys Arg Ser Val Glu D-Ala Ser Cys D-Ala Phe (SEQ ID NO: 14),

Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Ala (SEQ ID NO: 16),

wherein all amino acids, except for glycine, are of the L-absolute configuration, unless indicated as D-absolute configuration, and the peptide has a cyclic disulfide bond between Cys(182) and Cys(189) or Pen(182) and Pen(189) as appropriate, or an organic or inorganic acid addition salt thereof.

17. (Amended) A method for the treatment of obesity in an animal, which comprises administering to the animal an effective amount of a peptide according to claim 1.

34. (Amended) A method according to claim 17, wherein the peptide is administered orally.

36. (Amended) A pharmaceutical composition for use in the treatment of obesity in an animal, which comprises an effective amount of a peptide according to claim 1, together with one or more pharmaceutically acceptable carriers and/or diluents.